Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Toripalimab in Neoadjuvant Esophageal Squamous Cell Carcinoma
NCT05996484Phase 2Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Sep 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Nanfang Hospital, Southern Medical University. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05996484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05996484.